SetPoint Medical today announced they have appointed Dr. David Chernoff as chief medical officer.

The Valencia biomedical technology company develops bioelectronic therapy for chronic inflammatory conditions such as Crohn’s disease. Chernoff will oversee all clinical development activities for the company.

“The depth and breadth of David’s expertise in advancing and commercializing a wide range of products make him an ideal fit for SetPoint,” Anthony Arnold, chief executive at SetPoint Medical, said in a statement. “David is uniquely qualified to lead our clinical team as we prepare for the next phase of clinical development using our new proprietary bioelectronic medicine therapy.”

Bioelectronic therapy uses small implanted devices to deliver electrical pulses along existing physiologic pathways to trigger the body’s biological responses.

SetPoint is headquartered in the Mann Biomedical Park. Investors in the company include Boston Scientific and Medtronic among others.